News - Novartis, Sanofi


Current filters:


Popular Filters

Which place for orphan drugs in the strategy of pharma companies and payers?


As the 7th Rare Disease Day will be held on February 28, ALCIMED, an innovation and new business consulting…

Markets & MarketingNovartisPharmaceuticalPricingRare diseasesResearchRocheSanofi

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms


Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs


More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

Multiple sclerosis market could reach $18.3 billion in 2018


The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare…

AubagioBiogen IdecFinancialGilenyaGlobalNovartisPharmaceuticalSanofiTecfidera

India's NPPA says drugmakers cannot raise prices of imported products


At a meeting earlier this month, India's drug price regulator the National Pharmaceutical Pricing Authority…


Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene


There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming…


News briefs from Sanofi, Biogen/SOBI and Novartis


French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio


New data presented at the 28th congress of the European Committee for Treatment and Research in Multiple…

AlmirallAubagioBiotechnologyGenzymeGilenyaGW PharmaceuticalsNeurologicalNovartisPharmaceuticalResearchSanofiSativex

Sanofi moves on Lemtrada; Novartis Indian patent case


French drug major Sanofi's (Euronext: SAN) USA-based rare diseases subsidiary Genzyme is pulling leukemia…

Asia-PacificCampathEuropeGenzymeGlivecLegalLemtradaMarkets & MarketingNorth AmericaNovartisPatentsPharmaceuticalSanofi

Gap in patent filings for biological and small-molecule drugs widening, says Withers & Rogers


The number of patent applications filed by leading pharmaceutical companies for biological drugs has…

Abbott LaboratoriesBiotechnologyGlaxoSmithKlineNovartisPatentsPfizerPharmaceuticalResearchSanofi

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top